Novartis seeks Japan Stalevo nod as Parkinson's rivals multiply
This article was originally published in Scrip
Executive Summary
Responding to rapidly rising competition in the Parkinson's disease sector in Japan, Novartis has filed for the approval in the country of its single pill combination of carbidopa, levodopa and entacapone (licensed from Orion).